A Phase 2 interventional study of Suprachoroidal triamcinolone acetonide injection in Diabetic Macular Edema, sponsored by Khyber Girls Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Khyber Girls Medical College · Phase 2, Interventional, and Other
The goal of this clinical trial is to evaluate whether a single injection of suprachoroidal triamcinolone acetonide (SCTA) improves visual outcomes in patients with treatment-naive diabetic macular edema involving the center of the macula. The study will also evaluate the safety of SCTA by monitoring for possible side effects, including an increase in intraocular pressure and cataract progression.
Patients will be evaluated at the start of the study (baseline) and will receive one injection of SCTA. They will then be followed at 1, 3, and 6 months. At each follow-up visit, visual acuity, central macular thickness, intraocular pressure, and cataract status will be assessed to evaluate the effectiveness and safety of the treatment.
756 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's planned enrollment of 25 is below the median of 56 across 584 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Khyber Girls Medical College is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: adults aged ≥18 years with type 1 or type 2 diabetes mellitus and center-involving diabetic macular edema (DME), with best-corrected visual acuity (BCVA) between 6/12 and 6/60 (Snellen), central subfield thickness (CST) >320 µm on OCT macula (Spectralis SD-OCT), and diabetic retinopathy severity no worse than severe non-proliferative diabetic retinopathy (NPDR). The study eye must be treatment-naive, with no prior anti-VEGF therapy, intravitreal or periocular , or focal/grid laser for DME.
-
Exclusion Criteria: any other ocular disease compromising visual acuity (e.g., retinal vein occlusion, age-related macular degeneration, retinal detachment, uveitis, or vitreomacular traction/epiretinal membrane contributing to edema); a history of glaucoma, current use of IOP-lowering medication, or baseline IOP >21 mmHg; any intraocular surgery within the preceding 3 months; panretinal photocoagulation for severe NPDR or proliferative DR within the preceding 3 months; media opacity precluding reliable OCT imaging or fundus examination; a history of significant steroid-response IOP rise; or pregnancy/breastfeeding.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SCTA monotherapy
Drug: Suprachoroidal triamcinolone acetonide injection
4mg/0.1 ml, given once at baseline
Change in BCVA(logMAR) from baseline to 6 months
whether there is improvement in Visual acuity after SCTA
Time frame: from enrollment of participants to final outcome measurement at 6 month
change in Visual acuity
measured in logMAR
Time frame: from baseline to 6 months
No study locations are listed for this record.
Plan to share: Yes — IPD used in results
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.
Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Khyber Girls Medical College